T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

DISEASE CHARACTERISTICS:

Diagnosis of any of the following hematologic cancers or other diseases:

Acute myelogenous leukemia

Relapsed or refractory disease with poor-risk cytogenetics

Acute lymphoblastic leukemia

Relapsed or refractory disease with poor-risk cytogenetics

Chronic myelogenous leukemia

Persistent disease after at least 6 months of treatment with imatinib mesylate (Gleevec)

Myelodysplasia, meeting 1 of the following criteria:

French-American-British Classification of refractory anemia with excess blasts (RAEB) or RAEB with transformation
International Prognostic Scoring System score > 2

Lymphoid malignancies, including non-Hodgkin lymphoma, Hodgkin disease, chronic lymphocytic leukemia, and prolymphocytic leukemia

Relapsed or refractory disease after at least 1 prior therapy

Myelofibrosis

Transfusion dependent (RBC's, platelets, or both)
Paroxysmal nocturnal hemoglobinuria (transfusion dependent)
Myeloproliferative disorder
Eosinophilic leukemia

Severe aplastic anemia

Corrected reticulocyte count < 1%
Platelet count < 30,000/mm³ (untransfused)
Bone marrow biopsy with < 15% cellularity
Plasma cell leukemia
No essential thrombocytopenia or polycythemia vera
No matched related donor available
Must have an 8/8 or 7/8 serologic HLA matched unrelated donor available

PATIENT CHARACTERISTICS:

Cardiac ejection fraction ≥ 45% (if < 45%, then cardiac consult required)
Not pregnant or nursing
Negative pregnancy test
FEV_1 and DLCO ≥ 45% predicted
Creatinine < 2.0 mg/dL
Bilirubin < 2.0 mg/dL
HIV negative

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior allogeneic bone marrow transplantation
No concurrent administration of steroids with T-cell add-backs

INCLUSION CRITERIA:

Patient actual weight must not be greater than 1.5x their ideal body weight
Cardiac ejection fraction >45%. If less than 45%, a Cardiac consult will be obtained.
A suitably matched unrelated donor that is at least a 7 out of 8 HLA serologic match.
Patient is not pregnant.
FEV 1 and DLCO > 45% predicted on pulmonary function testing.
Serum creatinine <2.0 mg/dl, serum bilirubin <2.0 mg/dl.
Patient and donor are HIV negative.
Diagnosis of one of the following diseases
Acute myelogenous leukemia
Relapsed disease,
Refractory disease, or
With poor-risk cytogenetics
Acute lymphoblastic leukemia
Relapsed disease,
Refractory disease, or
With poor-risk cytogenetics
Chronic myelogenous leukemia
Persistent disease after at least 6 months of treatment with Imatinib Mesylate (Gleevec)
Myelodysplasia
FAB Classification of RAEB or RAEB-T -Or-
IPSS score >2
Lymphoid malignancies, including non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia and prolymphocytic leukemia
Relapsed or refractory disease after at least 1 prior therapy
Myelofibrosis
Transfusion dependence (RBC's, platelets, or both)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Transfusion dependent
Myeloproliferative Disorder
Eosinophilic Leukemia
Severe aplastic anemia (<1% corrected reticulocyte count, <30,000 untransfused platelet count, bone marrow biopsy with <15% cellularity)
Plasma cell leukemia
Patients with ET or PV will not be candidates unless their disease has transformed to end stage myelofibrosis or acute leukemia, for which eligibility criteria for myelofibrosis or acute leukemia would apply.
Patient must signed written informed consent.

EXCLUSION CRITERIA:

Inability to give informed consent
Absence of any of the above mentioned medical conditions
Availability of matched-related donor
History of prior allogeneic BMT